Zevra: Buy Rating Reaffirmed on Strong MIPLYFFA Momentum and U.S. NPC Opportunity; Price Target Maintained at $35
Tip Ranks·- Maxim Group analyst Jason McCarthy reaffirmed a buy rating on Zevra Therapeutics with a price target of 35.00 USD. - The rating is driven by strong Q2 results, robust gross margins, and the rapid adoption of MIPLYFFA. - Additional growth catalysts include significant opportunities in the U.S. NPC market and the ongoing vEDS DiSCOVER Phase 3 trial.